Yeojung Kim1,2, Sangwon Yun3, Keun-A Shin4, Woosuk Chung2,3, Youngkwon Ko2,3,4, Yoon-Hee Kim2,3,4, Chaeseong Lim2,3,4. 1. Department of Anesthesiology and Pain Medicine, Chungnam National University Sejong Hospital, Sejong 30099, Korea. 2. Department of Anesthesiology and Pain Medicine, Chungnam National University College of Medicine, Daejeon 35015, Korea. 3. Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, Daejeon 35015, Korea. 4. Research Institute for Medical Sciences, Chungnam National University College of Medicine, Daejeon 35015, Korea.
Abstract
Background and objectives: There are several studies that sevoflurane could enhance proliferation of cancer cells, while others suggest no effect on clinical outcome. We conducted in vivo and in vitro experiments to investigate the effects of sevoflurane, a volatile anesthetic, on proliferation and outcomes of Lewis lung carcinoma (LLC) cells. Materials and Methods: A total of 37 mice were injected with LLC cells to compare the tumor size and survival of the sevoflurane exposed group (sevo group) and control group. The sevo group was exposed to 2% sevoflurane and 4 L/min of oxygen for 1 h per day 3 times per week, and the control group was exposed only to 4 L/min of oxygen. In vitro study, 12 plates incubated with LCC cells. 6 plates were exposed to 2% sevoflurane for 1 hr/day for 3 days and 6 plates were not exposed, and cell proliferation was compared after 3 days. Results: There were no significant differences in survival or tumor size between mice exposed to sevoflurane and control mice (survival: 29.06 ± 4.45 vs. 28.76 ± 3.75, p = 0.836; tumor size: 0.75 (0.41-1.02) vs. 0.49 (0.11-0.79), p = 0.153). However, in vitro study, the proliferation of LLC cells exposed to sevoflurane increased by 9.2% compared to the control group (p = 0.018). Conclusions: Sevoflurane (2 vol%) exposure could promote proliferation of LLC cells in vitro environment, but may not affect proliferation of LLC cells in vivo environment. These results suggest that in vitro studies on the effects of anesthetics on cancer may differ from those of in vivo or clinical studies.
Background and objectives: There are several studies that sevoflurane could enhance proliferation of cancer cells, while others suggest no effect on clinical outcome. We conducted in vivo and in vitro experiments to investigate the effects of sevoflurane, a volatile anesthetic, on proliferation and outcomes of Lewis lung carcinoma (LLC) cells. Materials and Methods: A total of 37 mice were injected with LLC cells to compare the tumor size and survival of the sevoflurane exposed group (sevo group) and control group. The sevo group was exposed to 2% sevoflurane and 4 L/min of oxygen for 1 h per day 3 times per week, and the control group was exposed only to 4 L/min of oxygen. In vitro study, 12 plates incubated with LCC cells. 6 plates were exposed to 2% sevoflurane for 1 hr/day for 3 days and 6 plates were not exposed, and cell proliferation was compared after 3 days. Results: There were no significant differences in survival or tumor size between mice exposed to sevoflurane and control mice (survival: 29.06 ± 4.45 vs. 28.76 ± 3.75, p = 0.836; tumor size: 0.75 (0.41-1.02) vs. 0.49 (0.11-0.79), p = 0.153). However, in vitro study, the proliferation of LLC cells exposed to sevoflurane increased by 9.2% compared to the control group (p = 0.018). Conclusions: Sevoflurane (2 vol%) exposure could promote proliferation of LLC cells in vitro environment, but may not affect proliferation of LLC cells in vivo environment. These results suggest that in vitro studies on the effects of anesthetics on cancer may differ from those of in vivo or clinical studies.
Entities:
Keywords:
Lewis lung carcinoma; anesthetics; cancer; sevoflurane; survival
Authors: Richard Sullivan; Olusegun Isaac Alatise; Benjamin O Anderson; Riccardo Audisio; Philippe Autier; Ajay Aggarwal; Charles Balch; Murray F Brennan; Anna Dare; Anil D'Cruz; Alexander M M Eggermont; Kenneth Fleming; Serigne Magueye Gueye; Lars Hagander; Cristian A Herrera; Hampus Holmer; André M Ilbawi; Anton Jarnheimer; Jia-Fu Ji; T Peter Kingham; Jonathan Liberman; Andrew J M Leather; John G Meara; Swagoto Mukhopadhyay; Shilpa S Murthy; Sherif Omar; Groesbeck P Parham; C S Pramesh; Robert Riviello; Danielle Rodin; Luiz Santini; Shailesh V Shrikhande; Mark Shrime; Robert Thomas; Audrey T Tsunoda; Cornelis van de Velde; Umberto Veronesi; Dehannathparambil Kottarathil Vijaykumar; David Watters; Shan Wang; Yi-Long Wu; Moez Zeiton; Arnie Purushotham Journal: Lancet Oncol Date: 2015-09 Impact factor: 41.316
Authors: Laura L Benzonana; Nicholas J S Perry; Helena R Watts; Bob Yang; Iain A Perry; Charles Coombes; Masao Takata; Daqing Ma Journal: Anesthesiology Date: 2013-09 Impact factor: 7.892
Authors: Andrea Yap; Maria A Lopez-Olivo; Julia Dubowitz; Jonathan Hiller; Bernhard Riedel Journal: Can J Anaesth Date: 2019-03-04 Impact factor: 5.063